UBS AM
KALA icon

UBS AM’s KALA BIO KALA Stock Holding History

UBS AM’s Portfolio KALA Stock Details KALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-18
Closed -$120K – 2880
2021
Q3 		$120K Hold
18
– – ﹤0.01% 2718
2021
Q2 		$242K Buy
18
+10
+125% +$157K ﹤0.01% 2689
2021
Q1 		$142K Sell
8
-12
-60% -$234K ﹤0.01% 2581
2020
Q4 		$334K Buy
20
+1
+5% +$18.8K ﹤0.01% 2394
2020
Q3 		$362K Buy
19
+2
+12% +$46K ﹤0.01% 2264
2020
Q2 		$452K Buy
+17
New +$482K ﹤0.01% 2161
2018
Q1 		– Sell
-8
Closed -$366K – 2663
2017
Q4 		$366K Sell
8
-9
-53% -$421K ﹤0.01% 2063
2017
Q3 		$964K Buy
+17
New +$933K ﹤0.01% 1732

Other funds holding KALA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

UBS AM's KALA Position: Q4 2021 in Review

UBS AM sold out of KALA BIO (KALA) in Q4 2021, closing a stake of 18 shares — an estimated $120K sold.

UBS AM first reported a position in KALA in Q3 2017 and held it in 8 quarters. The position peaked at $964K in Q3 2017. 79 funds tracked by Wall St. Rank hold KALA as of Q4 2021.

  • UBS AM reported no remaining KALA BIO position as of Q4 2021 after selling out during the quarter.
  • UBS AM sold 18 KALA BIO shares in Q4 2021, an estimated $120K.
  • UBS AM first reported a position in KALA BIO in Q3 2017 and held it in 8 quarters.
  • UBS AM's KALA BIO position peaked at $964K in Q3 2017.
  • 79 funds tracked by Wall St. Rank held KALA BIO as of Q4 2021.

Based on UBS AM's 13F filing for Q4 2021, filed 14 Feb 2022.